🟢 Telix Pharmaceuticals is trading 4.16% up today after FDA approves Pixclara for glioma imaging

Telix Pharmaceuticals is trading 4.16% up at $11.73 after the FDA approved Pixclara for imaging gliomas.

• Pixclara is the first FDA-approved FET-PET imaging drug for brain cancer.
• The approval provides a clear company-specific catalyst and potential U.S. commercial opportunity despite broader weakness in major U.S. indexes.
• Telix scheduled investor presentations for September 14, 2026, supporting market attention.